Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSCD4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $43,626
Award facts
- Contract value 100% obligated
- $43,625.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $43,625.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. The delivery order, issued on January 12, 2026, with an ultimate completion date of February 3, 2026, carries no set-aside designation, indicating the award was made on an unrestricted competitive basis. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through the Defense Logistics Agency's Medical Supply Chain division. The company's portfolio encompasses a comprehensive range of pharmaceutical products including branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables. The PPV-G GEN V contract, awarded in November 2025 with a $499,999,999 ceiling value and completion date of December 31, 2036, positions DMS Pharmaceutical Group as a regional prime vendor contractor capable of fulfilling diverse and specialized pharmaceutical requirements for military medical operations globally. The company's performance on numerous prior delivery orders demonstrates its capability to support Department of Defense healthcare operations with consistent and reliable service.
Quick answers
Who was awarded contract SPE2DR26FSCD4?
SPE2DR26FSCD4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FSCD4 worth?
The government has obligated $43,626 on SPE2DR26FSCD4.
Is contract SPE2DR26FSCD4 an order under another contract?
Yes. SPE2DR26FSCD4 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCD4 competed?
The extent of competition for SPE2DR26FSCD4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award